Tarrytown, NY-based Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions including eye diseases, high LDL cholesterol.
Eye drug, Eylea, should continue to remain the key growth driver contributing significantly to the top line. The FDA approved its Dupixent (dupilumab) Injection for the treatment of adults with moderate-to-severe atopic dermatitis (AD). Kevzara (sarilumab), an anti interleukin (IL)-6 receptor monoclonal antibody was also approved in the United States for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs.
In this scenario, investor focus should remain on the performance of Eylea and uptake of Dupixent apart from the usual top-and bottom-line numbers.
Regeneron’s performance has been mixed so far. In the last four reported quarters, it surpassed earnings estimates on two occasions and missed in two. Overall, the company has recorded an average positive earnings surprise of 5.96%.
Currently, Regeneron has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Regeneron’s fourth-quarter 2017 earnings topped expectations. Our consensus called for EPS of $4.68 and the company reported EPS of $5.23.
Revenues: Revenues in the reported quarter also surpassed expectations. Regeneron posted revenues of $1.6 billion, compared to our consensus estimate of $1.5 billion.
Key Stats: Eylea net sales increased 14% year over year to $975 million in the United States. Dupixent sales came in at $139 million.
Check back later for our full write up on this REGN earnings report later!
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>